revyve™ Antimicrobial Wound Gel is a premium hydrogel that provides scientifically-proven efficacy for wound healing in an easy-to-use thermo-reversible gel, and is affordably priced for all settings of care. Why use any other hydrogel?
The Triple Threat Approach To Wound Care
Biofilm impaired healing - the largest unresolved problem in wound care.
Studies have reported a prevalence of biofilms in over 78% of chronic wounds. Biofilms are a glue-like substance excreted by bacteria and/or fungi to attach to surfaces. They protect and allow bacteria to survive and thrive in hostile environments. Biofilms make bacteria up to 1,000 times more resistant to antibiotics and antimicrobials and are one of the main contributors to antibiotic resistance.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. Kane®, StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™ and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.